Illumina launches new oncology menu for NovaSeq X Series customers

Rhea-AI Summary

Illumina Inc. (NASDAQ: ILMN) has expanded its oncology menu for NovaSeq™ X Series customers, launching high-throughput versions of TruSight™ Oncology 500 (TSO 500 HT) and TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). These assays enable labs to expand oncology testing research with improved sequencing economics, faster run times, and larger batch sizes.

The TSO 500 HT on NovaSeq X Series offers increased throughput and economic improvements compared to the NovaSeq 6000 System. TSO 500 ctDNA v2 provides a faster, more sensitive liquid biopsy CGP workflow from blood samples. Key improvements include 40% faster sequencing run times, a three-day total assay turnaround time, and ambient temperature shipping for consumables.

Positive

• Expansion of oncology menu for NovaSeq X Series customers
• Improved sequencing economics and faster run times for oncology testing
• Increased throughput capabilities compared to previous systems
• 40% faster sequencing run times for TSO 500 ctDNA v2
• Three-day total assay turnaround time for TSO 500 ctDNA v2
• Ambient temperature shipping for consumables, improving logistics

Negative

• None.

Insights

Medical Research Analyst

Illumina's launch of TSO 500 HT and TSO 500 ctDNA v2 on the NovaSeq X Series is a significant advancement in oncology research. This expansion allows for higher throughput and lower costs in comprehensive genomic profiling (CGP), which is important for personalized cancer treatment research.

The improved capabilities include:

• Faster sequencing run times (40% reduction)
• Three-day total assay turnaround time
• Broader batch sizes
• More sustainable logistics with ambient temperature shipping

These enhancements could accelerate the adoption of CGP in clinical oncology research, potentially leading to more rapid advancements in precision oncology. The expansion to benchtop systems later this quarter further increases accessibility for smaller labs.

Financial Analyst

This product expansion is likely to have a positive impact on Illumina's market position and financial performance. By offering improved economics and efficiency on their flagship NovaSeq X Series, Illumina is strengthening its competitive advantage in the oncology research market.

Key financial implications include:

• Potential for increased instrument sales as labs upgrade to NovaSeq X
• Higher consumables revenue from expanded use of TSO 500 assays
• Improved profit margins due to more efficient reagent economics

The expansion to benchtop systems could also open up new market segments. However, investors should monitor adoption rates and any potential cannibalization of existing product lines.

Oncology Doctor

The enhancements to Illumina's oncology menu represent a significant step forward for cancer research and potential clinical applications. The ability to perform comprehensive genomic profiling more efficiently and at a lower cost could accelerate our understanding of tumor biology and therapy selection.

Key benefits for oncology research include:

• Broader analysis of genetic variants and biomarkers in a single test
• Faster turnaround times, potentially speeding up research timelines
• Improved sensitivity in liquid biopsy assays, which could enhance early detection and monitoring capabilities

As CGP becomes more accessible, we may see increased integration into clinical practice, potentially leading to more personalized treatment strategies and improved patient outcomes in the future.

Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers

SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeq™ X Series customers. The company began offering the newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times, and broader batch sizes on the NovaSeq X Series for the first time.

"We are excited to deliver customers our flagship oncology assays, now fully tested and supported on the NovaSeq X," said Everett Cunningham, chief commercial officer of Illumina. "Empowering labs to scale distributed comprehensive genomic profiling serves to help advance the use of CGP in clinical oncology research and drive precision oncology forward."

Comprehensive genomic profiling (CGP) assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample to enable therapy selection research. CGP is increasingly included in recommended professional guidelines in oncology.

TSO 500 HT on the NovaSeq X Series offers increased throughput with impactful sequencing economic improvements, as compared to the NovaSeq 6000 System. Illumina announced today that it will expand TSO 500 HT to the company's benchtop NextSeq 1000 and NextSeq 2000 Systems later this quarter.

TSO 500 ctDNA v2 on the NovaSeq X Series enables a faster, more sensitive, and streamlined liquid biopsy CGP workflow from minimally invasive blood samples for solid tumor therapy selection research, now in a fully supported and verified workflow.

Laura Knight, global VP of Genomic Services at Almac Diagnostic Services, said: "As a leader in next-generation sequencing diagnostics and research, Almac is delighted that Illumina TSO 500 ctDNAv2 is now being made available on the NovaSeq X Plus platform to enable comprehensive genomic profiling. The NovaSeq X Plus compatibility takes molecular analysis of blood-based biomarkers to new levels."

TSO 500 ctDNA v2 offers improvements including transformative sequencing economics; faster sequencing run times by about 40%, resulting in a three-day total assay turnaround time; and more sustainable logistics, with ambient temperature shipping for consumables.

"With increased throughput, faster turnaround time, and optimized reagent economics, Almac can now accelerate oncology research and diagnostic development," Knight added. "We believe that the TSO500 ctDNA v2 assay, combined with the power of NovaSeq X Plus, represents a transformative advancement in precision medicine."

About the TruSight Oncology 500 portfolio

The TSO 500 portfolio is a research-use-only pan-cancer portfolio that enables comprehensive genomic profiling from either tissue or liquid (blood) biopsies. Designed to identify known and emerging tumor biomarkers across 523 genes, the TSO 500 portfolio utilizes both DNA and RNA (DNA only for liquid biopsy analysis) from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants (single nucleotide variants, indels), fusions, splice variants, and copy number variants. In addition, it assesses key genomic signatures, such as tumor mutational burden (TMB), microsatellite instability (MSI), and Homologous recombination deficiency (HRD).

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; and (iii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. 

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
Samantha Beal
PR@illumina.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-new-oncology-menu-for-novaseq-x-series-customers-302214084.html

SOURCE Illumina, Inc.

FAQ

What new oncology products did Illumina (ILMN) launch for NovaSeq X Series in August 2024?

Illumina launched high-throughput versions of TruSight Oncology 500 (TSO 500 HT) and TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) for NovaSeq X Series customers.

How does TSO 500 ctDNA v2 on NovaSeq X Series improve sequencing run times for Illumina (ILMN)?

TSO 500 ctDNA v2 on NovaSeq X Series offers approximately 40% faster sequencing run times, resulting in a three-day total assay turnaround time.

What are the key benefits of Illumina's (ILMN) new oncology menu for NovaSeq X Series?

The key benefits include improved sequencing economics, faster run times, larger batch sizes, increased throughput, and more sustainable logistics with ambient temperature shipping for consumables.

When will Illumina (ILMN) expand TSO 500 HT to NextSeq 1000 and NextSeq 2000 Systems?

Illumina announced that it will expand TSO 500 HT to the company's benchtop NextSeq 1000 and NextSeq 2000 Systems later in the quarter of the announcement (Q3 2024).